文献速递肿瘤 PET/CT放射性药物与辐射防护

GRPR拮抗剂[68Ga]Ga-NOTA-PEG2-RM26在前列腺癌和乳腺癌患者中的首次人体辐射剂量学研究

First-in-human radiation dosimetry of the GRPR antagonist [68Ga]Ga-NOTA-PEG2-RM26 in patients with prostate and breast cancer.
PubMed 文献 · EJNMMI Res · 2026-06-18

该研究基于12例癌症患者(6例女性乳腺癌、6例男性前列腺癌)注射[68Ga]Ga-NOTA-PEG2-RM26后六个时间点的PET-CT显像及尿液收集,评估人体辐射剂量学。结果显示胰腺吸收剂量最高(110 ± 43 µGy/MBq),其次为膀胱壁(100 ± 36 µGy/MBq)和肾脏(31 ± 11 µGy/MBq);有效剂量(ICRP 103)为11 µSv/MBq。70kg标准人注射140MBq时有效剂量为1.5 mSv,低于或与其他68Ga标记GRPR靶向配体相当。

要点

  • 胰腺是吸收剂量最高的器官,为110 ± 43 µGy/MBq。
  • 膀胱壁和肾脏吸收剂量分别为100 ± 36和31 ± 11 µGy/MBq。
  • 70kg标准人注射140MBq时有效剂量为1.5 mSv。

核心结论

  • 70kg标准人接受140MBq [68Ga]Ga-NOTA-PEG2-RM26时有效剂量为1.5 mSv,低于或与其他68Ga标记GRPR靶向放射性配体相当。

研究设计与样本

  • 首次人体辐射剂量学研究,纳入12例癌症患者(6例女性乳腺癌、6例男性前列腺癌),基于注射后六个时间点PET-CT显像及尿液收集,使用OLINDA/EXM 2.3.0软件进行剂量学评估。

主要发现

  • 胰腺、肝脏、脾脏、肾实质、胆囊、膀胱内容和皮质骨被确定为源器官/区域。
  • 胰腺吸收剂量最高,为110 ± 43 µGy/MBq,其次为膀胱壁100 ± 36 µGy/MBq和肾脏31 ± 11 µGy/MBq。
  • 骨生成细胞吸收剂量为15 ± 7 µGy/MBq。
  • 4小时内经尿液排出的总活度中位数为注射活度的56%(范围43-75%)。
  • 采用膀胱模型1小时排尿间隔计算,有效剂量(ICRP 103)为11 µSv/MBq。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gastrin-releasing peptide receptor (GRPR) is overexpressed in several malignant tumours, while its physiological expression in major organs, except for pancreas, is low. GRPR is therefore an interesting target in nuclear medicine. The GRPR-binding ligand, [68Ga]Ga-NOTA-PEG2-RM26 has previously been proven safe in humans. This study evaluates human dosimetry of the radioligand using 12 cancer patients (6 women with breast cancer and 6 men with prostate cancer) based on PET-CT imaging at six timepoints post injection. The voided urine was also collected to serve as an input to a urinary bladder model. RESULTS: The pancreas, liver, spleen, kidney parenchyma, gall bladder, urinary bladder contents and cortical bone were identified as source organs/regions. Results using OLINDA/EXM 2.3.0 dosimetry software showed that pancreas was the organ that received the highest absorbed dose, 110 ± 43 µGy/MBq, followed by the urinary bladder wall, 100 ± 36 µGy/MBq, and the kidneys, 31 ± 11 µGy/MBq. The osteogenic cells received 15 ± 7 µGy/MBq. The median (range) of the total excreted activity through urine was 56% (43-75%) of the injected activity in 4h. The effective dose (ICRP 103) from an injection of [68Ga]Ga -NOTA-PEG2-RM26 was calculated to 11 µSv/MBq, using a 1h voiding interval in the urinary bladder model. CONCLUSION: A standard person of 70kg receiving 140MBq of [68Ga]Ga-NOTA-PEG2-RM26 will receive an effective dose of 1.5 mSv, which is lower or in accordance with other 68Ga-labelled GRPR targeted radioligands. TRIAL REGISTRATION: Clinicaltrials.gov, NCT06147362, Registered 17 November 2023 - Retrospectively registered, https://www. CLINICALTRIALS: gov/study/NCT06147362.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Bjäreback A, Estenberg U, Tzortzakakis A, et al. First-in-human radiation dosimetry of the GRPR antagonist [68Ga]Ga-NOTA-PEG2-RM26 in patients with prostate and breast cancer. EJNMMI Res. 2026. PMID: 42310173. doi:10.1186/s13550-026-01472-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。